Skip to main content
. 2012 Jul;97(7):1036–1041. doi: 10.3324/haematol.2011.053918

Figure 1.

Figure 1.

Kaplan-Meier standardized overall survival curves of three patient groups. Standardized survival of RARS-T is shorter than ET patients (median survival 76 months vs. 115 months, log rank test: P<0.001) but also longer than RARS patients (median survival 76 months vs. 63 months, P<0.001). ET: essential thrombocythemia; RARS: refractory anemia with ring sideroblasts; RARS-T: refractory anemia with ring sideroblasts and marked thrombocytosis.